Just a few weeks after ending four oncology deals worth at least US$2.1 B in its latest termination spree, Janssen Biotech is filling the void by licensing Yuhan Corporation’s lazertinib for the treatment of non-small cell lung cancer. The agreement gives Janssen the worldwide rights, excluding Korea, to lazertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor that showed encouraging interim Phase I/II data in June 2018. A joint clinical trial is expected to begin in 2019.